Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.

Robert H. Jones,Margherita Carucci,Angela C. Casbard,Rachel Butler,Fouad S Alchami,C Bale,Pavel Bezecny,Johnathan Joffe,Sarah Moon,Chris Twelves,Ramachandran Venkitaraman,Simon Waters,Sacha J Howell

Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.

2019

Robert H. Jones
Margherita Carucci
Angela C. Casbard
Rachel Butler
Fouad S Alchami
C Bale
Pavel Bezecny
Johnathan Joffe
Sarah Moon
Chris Twelves
Ramachandran Venkitaraman
Simon Waters
Sacha J Howell

1005Background: The PI3K/AKT signalling pathway is frequently activated in patients (pts) with estrogen receptor (ER) positive breast cancer (ER+BC) and has been implicated in endocrine therapy res...

Keywords:

PI3K/AKT/mTOR pathway
Placebo
Aromatase inhibitor
Estrogen receptor
Endocrine system
Pathology
Fulvestrant
Breast cancer
Protein kinase B
Oncology
Internal medicine
Medicine
in patient
double blind

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations